Kathleen Meyer

Board-certified toxicologist specializing in the nonclinical development of small and large molecule therapeutics. She has directed toxicology, pharmacokinetics, bioanalytical development and animal resources groups, lead project teams and subteams, and mentored many scientists. She has experience defending nonclinical development plans to US, EU and Japanese regulatory authorities. Sangamo BioSciences, BioMarin, XOMA, Elan Pharmaceuticals.